External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

<ul><li>Acasti Pharma is making progress in developing IV nimodipine for acute subarachnoid hemorrhages</li><li>Lead asset GTX-104 is the primary focus of their development efforts</li><li>Successful PIPE offering and enrollment in Phase 3 trial put Acasti Pharma on track for potential FDA approval</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Acasti Pharma is making progress in developing IV nimodipine for acute subarachnoid hemorrhagesLead asset GTX-104 is the primary focus of their development effortsSuccessful PIPE offering and enrollment in Phase 3 trial put Acasti Pharma on track for potential FDA approvalThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Acasti Pharma Inc (ACST) - Wednesday, Jul 10, 2024

United States

Grace Therapeutics, Inc. operates as a late-stage biopharma company. The Company focuses on drug delivery and technologies addressing rare and orphan diseases. Grace Therapeutics serves clients in Canada and the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Grace Therapeutics (GRCE US)

Acasti Pharma Inc (ACST) - Wednesday, Jul 10, 2024

Acasti Pharma is making progress in developing IV nimodipine for acute subarachnoid hemorrhages. Lead asset GTX-104 is the primary focus of their...

Value Investors Club (VIC)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)